Announcement of termination of co-promotion of anti-depressant, Paxil CR Tablets

GlaxoSmithKline K.K. (President: Philippe Fauchet, Head Office: Shibuya-ku, Tokyo) and Sumitomo Dainippon Pharma Co., Ltd. (President: Masayo Tada, Head Office: Chuo-ku, Osaka) announced today that the companies have reached an agreement to terminate the co-promotion of GlaxoSmithKline K.K’s anti-depressant Paxil ® CR Tablets 12.5mg and Paxil ® CR Tablets 25mg (paroxetine hydrochloride hydrate, hereinafter referred to as Paxil ® CR , CR stands for Controlled Release) as of end of December 2014. The co-promotion activity by the 2 companies was started in April 2012, with the objective of accelerating the providing and collecting of proper prescribing information on Paxil ® CR , so that this medication can support patients suffering from depression. From January 2015, GlaxoSmithKline K.K. will solely be responsible for providing information on Paxil ® CR. GlaxoSmithKline K.K. and Sumitomo Dainippon Pharma Co., Ltd. will continue to contribute to medicine through providing and collecting of proper prescribing information of individual products.

The release as fetched from its publisher. sumitomo-pharma.com ↗